BRUSSELS and WASHINGTON — In a high-stakes trade negotiation, European Union trade negotiators have formally presented the United States with a detailed exemption list seeking carve-outs for approximately €150 billion to €155 billion worth of European goods from the newly implemented US import tariffs.
The push follows the implementation of the 2025 "Turnberry Deal" framework, negotiated between European Commission President Ursula von der Leyen and US President Donald Trump at Turnberry, Scotland. Under the agreement, a baseline 15% tariff is applied to most European exports entering the US, in exchange for the EU removing its own duties on US industrial goods—a commitment the EU completed on July 1, 2026. Now, EU trade officials are seeking critical carve-outs to protect highly integrated supply chains, medical technologies, and heritage consumer exports.
The Turnberry Trade Framework: Zero EU Duties vs. U.S. Baseline Tariffs
The current trade dispute stems from the structural asymmetry established by the Turnberry trade agreement. While the EU agreed to a comprehensive removal of its import duties on US industrial goods, the U.S. implemented a blanket 15% tariff across major categories of European imports. The U.S. and EU agreed in a joint statement to "consider the possibility" of returning to pre-deal tariff levels (which averaged 3.3% for industrial goods) for strategic products, but the U.S. refused to initiate those discussions until the EU's tariff cuts were fully enacted.
With the EU having lifted its industrial duties, Brussels has launched a major diplomatic push. Negotiations held on July 14–15, 2026, in Washington saw the European Commission present a comprehensive list of hundreds of product lines, arguing that these goods are either critical to transatlantic supply chains or have no viable domestic substitutes within the U.S. market.
Critical Impact on the MedTech and Life Sciences Sectors
Unlike previous trade agreements where pharmaceutical and medical technology products were kept strictly duty-free under the GATT Pharmaceutical Agreement, the Turnberry deal did not include a blanket exemption for medical hardware. Consequently, a 15% tariff is being applied to European-manufactured diagnostic equipment, orthopedic implants, cardiovascular catheters, and active pharmaceutical ingredients (APIs).
The stakes are nowhere higher than in Ireland, which has emerged as Europe's second-largest exporter of medical technology. Ireland's MedTech sector generates over €13 billion in annual exports and employs roughly 48,000 people across clusters in Galway, Limerick, Cork, and Dublin. The United States is Ireland's largest single market for medical technology, absorbing more than 40% of its total exports.
"The transatlantic medical technology supply chain is highly integrated. Many Irish-manufactured sub-assemblies are exported to the US for sterilization, final packaging, or software integration, before being re-exported. Imposing a 15% tariff at the U.S. border directly increases costs for healthcare providers and clinical labs, ultimately impacting patient care costs in the United States."
Visualizing the Exposure: The €150 Billion Tariff Exemption List
The European Commission’s requested exemption list covers multiple sectors. The visual breakdown below illustrates the estimated economic value and exposure of the primary goods categories targeted for tariff relief:
EU Exemption List: Value Breakdown by Export Sector
Estimated export value of goods presented by Brussels for U.S. tariff carve-outs (in Billions of Euros).
Whiskey, Agriculture, and Consumer Goods: The Broader Trade War
Beyond high-tech industrial and medical equipment, the EU’s exemption push covers iconic consumer exports. The European list includes spirits, wine, beer, olive oil, Roquefort cheese, and pasta. Specifically, negotiators are pushing for exclusions for Irish whiskey and Scotch whisky, which were hit hard during previous trade skirmishes.
European producers argue that these regional products cannot be replicated in the United States due to strict Geographical Indication (GI) protections, making the tariffs punitive to American consumers rather than stimulative to domestic production.
| Target Product Category | Estimated Exposure | EU Negotiation Rationale |
|---|---|---|
| Medical Devices & Health Tech | €45 Billion | Tariffs directly raise U.S. patient care and surgical cost structures; lack of equivalent domestic FDA-validated capacity for specific implants. |
| Industrial Electronics & Robotics | €55 Billion | Exemptions requested for factory automation components where U.S. re-shoring initiatives rely on European tooling. |
| Irish Whiskey & Scotch Whisky | €8 Billion | Protected geographical indicators; high-value products with zero direct U.S. manufacturing equivalents. |
| High-Value Food (Cheese, Olive Oil) | €17 Billion | Protected regional food exports (e.g., Parmigiano-Reggiano, Greek olive oil) that serve distinct consumer markets. |
transatlantic Business Outlook: Hard Bargaining Ahead
Negotiations are expected to be exceptionally challenging. U.S. trade officials have signaled that the administration intends to maintain the integrity of the 15% tariff baseline to encourage localized manufacturing and offset trade imbalances. Furthermore, the EU is simultaneously pressing for the resolution of long-standing 50% U.S. tariffs on European steel and aluminum, complicating the broader trade agenda.
For European manufacturers, particularly in Ireland’s highly exposed MedTech sector, the immediate strategy must focus on supply chain resilience and cost management. Companies are already examining tariff-mitigation strategies, such as setting up duty-drawback programs, utilizing Foreign Trade Zones (FTZs) in the U.S., or shifting secondary packaging and sterilization operations to the U.S. to alter the rules of origin and reduce the declared customs value of imported components.
Conclusion
The battle over the €150 billion exemption list will define transatlantic commercial relations for the remainder of 2026. While the EU has fulfilled its side of the Turnberry Deal by removing industrial tariffs, the U.S. administration's protectionist stance indicates that any carve-outs will be hard-won. MedTech manufacturers and agricultural exporters alike must prepare for a prolonged period of tariff exposure, adapting their operational footprints to a post-globalization trade landscape.
Sources & References:
1. Irish Independent: EU seeks tariff relief on €155bn of European goods, including medical devices and whiskey (July 2026).
2. Euronews: EU pushes US to exempt €150 billion worth of EU goods under Turnberry Deal framework (July 2026).
3. Yahoo Finance: Transatlantic trade: Brussels seeks carve-outs from 15 percent U.S. tariffs (July 2026).
4. European Commission Directorate-General for Trade: Bilateral trade statistics and Turnberry Deal compliance updates.
